OrganiGram is a medical cannabis provider as well as a seller of cannabis to adult recreational consumers. Expectations from analysts are quite beneficial. According to analysts, net sales growth ...

Would you buy that Atlantic Canada marijuana stock? The stock in question is OrganiGram Holdings (NASDAQOTH: OGRMF). Had you bought OrganiGram in early 2016 and held on, you'd now be sitting on an ...

“The acquisition of Collective Project marks yet another strategic milestone towards Organigram’s global leadership ambitions. Not only does this acquisition represent our first commercial ...

ROME, Oct. 2, 2020 /PRNewswire/ -- There is good news today for the world's most vulnerable and marginalised rural communities, as the International Fund for Agricultural Development (IFAD ...

During Q2, OrganiGram reported net revenue of 23.2 million Canadian dollars. That's down from the prior-year quarter when it reported gross sales of CA$26.9 million. What's most concerning is that ...

Sales were up this past quarter after a bad showing in Q2. OrganiGram officially opened its "Centre of Excellence" to develop more products to bring to market. Rising expenses and abysmal margins ...

Organigram's new nanoemulsion technology, FAST, promises faster onset and improved bioavailability for cannabis ingestibles. Organigram plans to launch FAST technology in fall 2024 with gummies ...

Beena Goldenberg to retire as CEO of Organigram (NASDAQ: OGI) at the end of fiscal 2025 (Sept. 30) Under her leadership, revenue grew from $80M to over $250M and Organigram became Canada’s ...

In the context of rising global food insecurity, the UN International Fund for Agricultural Development (IFAD) plays a unique role supporting food-insecure countries. As an international financial ...

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is ...

Unlike many Canadian cannabis producers, OrganiGram Holdings (NASDAQ: OGI) is beating the broader market so far in 2019. But the year-to-date gain of more than 38% for the stock is still well ...